---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-018234"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:12:56.784118+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma: pediatric Netherton Syndrome patient shows dramatic skin healing after 2 weeks of QRX003

## Summary
- IGA score improved from 7 to 1-2 (0-10 scale) after two weeks of whole-body QRX003 treatment.
- Pruritus (itch) score reduced from 5 to 1; patient stopped all antihistamines, glucocorticoids, and antivirals.
- Patient now experiences zero nightly sleep disturbances for first time; no adverse events reported.
- First pediatric patient data from ongoing Investigator Pediatric Netherton Syndrome study.

## SEC filing metadata
- accession: 0001104659-25-018234
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925018234/0001104659-25-018234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925018234/tm257848d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-018234
- JSON: https://secwatch.observer/filing/0001104659-25-018234.json
- Plain text: https://secwatch.observer/filing/0001104659-25-018234.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.